[Skip to Navigation]
Views 426
Citations 0
Comment & Response
April 30, 2020

Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer—Reply

Author Affiliations
  • 1State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
  • 2The Medical Department, 3D Medicines Inc, Shanghai, China
JAMA Oncol. 2020;6(7):1116-1117. doi:10.1001/jamaoncol.2020.0646

In Reply We appreciate the interest and comments by colleagues on our recent systematic review and meta-analysis comparing anti–programmed cell death 1 (PD-1) vs anti–programmed cell death ligand 1 (PD-L1) treatments in patients with cancer.1 Below is our brief response; answers for the other questions can be mostly found in the article and will not be addressed here because of the space limit.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words